论文部分内容阅读
目的:研究藏药郎庆阿塔对复合因素所致大鼠肝纤维化的治疗作用。方法:清洁级Wistar大鼠90只采用复合因素(高脂低蛋白饲料喂养、含乙醇饮用水加皮下注射四氯化碳)制备大鼠肝纤维化模型,造模6周末随机处死12只造模大鼠,通过肝组织病理检查及血清肝功能指标来检查肝纤维化模型成功率。将模型大鼠随机分为模型对照组、阳性药复方鳖甲软肝片组(0.55 g.kg-1)、郎庆阿塔颗粒给药高、中、低剂量组(生药11.4,5.7,2.85 g.kg-1),另设正常对照组。各组大鼠于分组后即日(第7周)开始ig给药,每日1次,连续ig给药7周。治疗结束后,检测血清中生化指标和肝纤维化指标,并取肝脏组织,测定肝脏组织中羟脯氨酸含量、超氧化物歧化酶(SOD)活力及丙二醛(MDA)水平,另取肝脏组织标本进行病理组织学检查。结果:郎庆阿塔能明显降低肝纤维化大鼠增高的肝脏系数和肝组织中羟脯氨酸含量(P<0.05～P<0.01),显著降低肝纤维化大鼠血清中异常升高的天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)、碱性磷酸酶(ALP)、总胆红素(T-BIL)、透明质酸(HA)、层黏连蛋白(LN)、Ⅲ型前胶原氨端肽(PⅢNP)及Ⅳ型胶原(CⅣ)(P<0.05～P<0.01),升高白蛋白(ALB)和A/G比值,能明显升高肝组织中SOD活力(P<0.05～P<0.01)、降低异常升高的MDA水平(P<0.05～P<0.01),病理组织学检查结果表明郎庆阿塔高、中剂量对肝纤维化大鼠肝纤维组织增生、肝组织炎症活动度均有显著的改善作用(P<0.05～P<0.01),并能显著降低肝组织中胶原纤维面积(P<0.05～P<0.01)。结论:藏药郎庆阿塔具有明显的治疗肝纤维化作用。
OBJECTIVE: To study the therapeutic effect of Tibetan medicine Lan-qing Atta on hepatic fibrosis induced by multiple factors in rats. Methods: Ninety clean-grade Wistar rats were used to make the model of hepatic fibrosis in rats by compound factors (high-fat and low-protein diet, ethanol-drinking water and subcutaneous injection of carbon tetrachloride) Rats, liver tissue pathology and serum liver function indicators to check the success rate of liver fibrosis models. The model rats were randomly divided into model control group, the positive drug compound Biejia Rugan group (0.55 g.kg-1), Lang Qing Atta pellets administered high, medium and low dose group (crude drug 11.4,5.7,2.85 g.kg-1), another set of normal control group. The rats in each group started ig administration once daily (week 7) once a day for 7 weeks. After the treatment, the serum biochemical indexes and hepatic fibrosis indexes were detected, and the liver tissues were taken for determination of hydroxyproline content, superoxide dismutase (SOD) activity and malondialdehyde (MDA) level in the liver tissue, Liver tissue specimens for histopathological examination. Results: Lang Qing Atta could significantly reduce the hepatic coefficient and hydroxyproline content in hepatic fibrosis rats (P <0.05 ~ P <0.01), and significantly reduce the abnormally elevated serum levels in hepatic fibrosis rats AST, ALT, ALP, T-BIL, HA, LN, (PⅢNP) and type Ⅳ collagen (CⅣ) (P <0.05 ~ P <0.01). Increasing albumin (ALB) and A / G ratio could significantly increase the activity of SOD in liver tissue P <0.05 ~ P <0.01), and decreased the level of abnormally elevated MDA (P <0.05 ~ P <0.01). The results of histopathological examination showed that high and medium doses of Langqingtai had a significant effect on the hepatic fibrosis in rats with hepatic fibrosis (P <0.05 ~ P <0.01), and significantly reduced the area of collagen fibers in liver tissue (P <0.05 ~ P <0.01). Conclusion: Tibetan medicine Lang Qing Atta has a significant effect on the treatment of liver fibrosis.